# A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease

> **NCT01685437** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 189 (actual)

## Conditions studied

- Peyronie's Disease

## Interventions

- **BIOLOGICAL:** AA4500

## Key facts

- **NCT ID:** NCT01685437
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2017-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01685437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01685437, "A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01685437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*